Oxford, UK, 14 January 2019 - Oxfordshire companies which are progressing valuable innovations can apply now for The Oxford Science Park Innovation Award, one of 2019's Oxfordshire Business Awards (OXBA). The Oxford Science Park, one of the UK's leading parks for science and technology companies, is pleased to be sponsoring the award for the fourth year.
EVONETIX LTD today announced it has appointed Stephanie Brooking as Head of Product Management. Evonetix aims to utilise its innovative silicon chip approach to deliver a high-throughput solution for the synthesis and assembly of DNA molecules with high fidelity. Stephanie will help to define the Company’s strategy for market entry and longer-term product marketing for its novel gene synthesis products.
Arecor Limited is pleased to announce its participation at PEPTalk 2019’s Protein Science Week. This leading international conference and one of the largest annual gatherings of over 1,300 protein science researchers in the world, will be held between January 14-18, 2019, at the Hilton Hotel, San Diego Bayfront, San Diego, California, USA.
CHAIN has just put out a press release regarding our recent runner-up placement in the EuropaBio Biotech SME Awards, where we won a two-year membership of EuropaBio. We would be very grateful if you could circulate among the BIA network.
The news was announced on our website today: https://chainbiotech.com/2019/01/09/chain-awarded-europabio-membership/
Kind regards & Happy New Year,
Locate Bio Ltd (“Locate”), a cell and gene therapy platform company, has received notification that it will be granted key patents covering its IntraStem intracellular delivery system in the United States and Europe.
Horizon Discovery Group plc (AIM: HZD), a global leader in the application of gene editing and gene modulation technologies, today announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc (AIM: C4XD) ("C4XD"), a pioneering drug discovery company.
Synthace Ltd today announced the closing of a $25.6m Series B financing round led by Horizons Ventures with additional investment from Luminous Ventures, SOSV and select other individual and large family office investors. Synthace will use the new funds to drive continued product development and build upon its cell and gene therapy customer base to accelerate global awareness of its solutions.
LifeArc, a leading UK medical research charity, is delighted to launch a new Technology Transfer Fellowship programme in partnership with Imperial Innovations, Queen Mary Innovation and UCL Business (UCLB), the technology transfer offices for Imperial College London, Queen Mary University London and University College London, respectively. The new initiative will provide successful Fellowship applicants with training and experience in four of London’s leading technology transfer environments.